Type to search

Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial | Pharmtech Focus
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial | Pharmtech Focus
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate (NanoFlu/NVX-CoV2373) | Pharmtech Focus